<DOC>
	<DOCNO>NCT00049829</DOCNO>
	<brief_summary>HORIZON-PFT ( Pivotal Fracture Trial ) study effect zoledronic acid , give per year , treatment osteoporosis woman past menopause . Hip vertebral fracture devastate consequence osteoporosis . HORIZON-PFT design determine benefit zoledronic acid fracture reduction hip spine .</brief_summary>
	<brief_title>HORIZON-PFT : Pivotal Fracture Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Female , 6589 year old No history severe liver , kidney eye disease Current bisphosphonate user Aredia® ( pamidronate ) , Didronel® ( etidronate ) , Fosamax® ( alendronate ) , Actonel® ( risedronate ) , Skelid® ( tiludronate ) Using hip protector Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Bisphosphonate , BMD , Height loss , Hip protector , HRT ,</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>